David Thompson

David Thompson is an experienced professional with a diverse background in the healthcare industry. David most recently served as the Chief Executive Officer at Osteal Therapeutics, a role they have held since August 2020. Prior to this, they were an Executive Advisor at UCSF Rosenman Institute, starting in May 2020.

From 2018 to 2020, David was involved with Gravitas Medical, where they served as the Interim CEO and a Member of the Board of Directors. Gravitas Medical focuses on developing a non-invasive patient monitoring system for optimizing nutrition delivery in acute care settings.

Before their time at Gravitas Medical, David held various roles at Smith & Nephew, starting in 2015. David was the Vice President of Strategic Development, overseeing worldwide product pipeline and business strategies for multiple franchises.

From 2010 to 2015, David worked as the Managing Director at Thompson Partners, an international consultancy specializing in marketing and commercialization for the medical device and healthcare industries.

David's earlier experience includes roles at BARRX Medical, Medtronic's Kyphon Division, Kyphon, The Clorox Company, and Bain & Co. In these positions, they gained expertise in global marketing, product development, and brand management.

Overall, David Thompson has a solid track record of leadership and strategic expertise in the healthcare industry, particularly in medical devices and consumer healthcare sectors.

David Thompson pursued their Bachelor's degree in Political Science and International Relations at UCLA, although the specific start and end years are not available. Following this, they attended the University of California, Berkeley, Haas School of Business where they obtained an MBA in Business Administration from 2001 to 2003.